Skip to content

Comparative study of sedation regimens using etomidate and propofol under monitoring of Bispectral Index during gastroscope

Comparative study of sedation regimens using etomidate andpropofol under monitoring of Bispectral Index during gastroscope

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15007232
Enrollment
Unknown
Registered
2015-09-21
Start date
2015-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

digestive diseases

Interventions

SP:sufentanil 0.1 ug/kg+propofol 1.5mg/kg induce, propofol 0.5mg/kg every time maintain
SEP:sufen 0.1 ug/kg+propofol 0.5mg/kg+etomidate 0.2mg/kg induce, propofol 0.5mg/kg every time maintain
SE:sufentanil 0.1 ug/kg+etomidate 0.25mg/kg induce, etomidate 0.1mg/kg every time maintain

Sponsors

Department of Anesthesiology, West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria included patients aged 18-65 years who scheduled to undergo colonoscopy within 60 min, gender not limited, Body mass index (BMI) 18.5 ~ 30 kg/m2,ASA I ~ III.

Exclusion criteria

Exclusion criteria: Exclusion criteria included cardiac, pulmonary, hepatic or nephritic disease, metabolic disease, abnormal anesthesia recovery, acute airway inflammation in the past 2 weeks,blood pressure >180/110 mmHg and/or diastolic blood pressure > 110 mmHg,or blood pressure < 90/60mmHg, neuromuscular disease,Hemoglobin is less than 70 g/L, possible or happened difficult airway, allergy to emulsion or opioid, hormones or adrenal cortex inhibitors over 3 weeks, electrolyte disturbance.

Design outcomes

Primary

MeasureTime frame
mean arterial pressure;Onset BIS value;

Secondary

MeasureTime frame
heart rate;Pulse oximetry;Onset time;recovery time;leaving time;

Countries

China

Contacts

Public ContactXiao Wang
1490829116@qq.com+86 18980601549

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026